An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics.
Eleven schizophrenics (7 females) displaying an acute psychotic episode received the partial dopamine agonist terguride in doses up to 2 mg per day. Improvement in terms of positive symptoms reduction was observed in two cases only. In contrast, in a previous clinical trial targeted at negative schizophrenic symptoms, the majority of the patients appeared to have benefited from terguride application.
Central Institute of Mental Health, Mannheim, Federal Republic of Germany.
R
R
Olbrich
H
H
Schanz
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008090:Lisuride / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011581:Psychological Tests; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012563:Schizophrenia, Paranoid / Q000188:drug therapy / Q000503:physiopathology
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; C006208:dironyl; D008090:Lisuride